Anzeige
Mehr »
Login
Dienstag, 29.09.2020 Börsentäglich über 12.000 News von 644 internationalen Medien
Versprochen und gehalten! Heute der Bruch des High-Level-Widerstands!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 509722 ISIN: SE0000722365 Ticker-Symbol: OMAX 
Berlin
29.09.20
18:46 Uhr
0,402 Euro
-0,006
-1,57 %
Branche
Pharma
Aktienmarkt
General Standard
1-Jahres-Chart
OASMIA PHARMACEUTICAL AB Chart 1 Jahr
5-Tage-Chart
OASMIA PHARMACEUTICAL AB 5-Tage-Chart

Aktuelle News zur OASMIA PHARMACEUTICAL Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.09.Edison Investment Research Limited: Edison issues initiation on Oasmia Pharmaceutical (OASM)187DJ Edison Investment Research Limited: Edison issues initiation on Oasmia Pharmaceutical (OASM) Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation...
► Artikel lesen
OASMIA PHARMACEUTICAL Aktie jetzt für 0€ handeln
09.09.Oasmia Pharmaceutical - An appealing metamorphosis138Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs through its proprietary XR-17 platform technology. Its technology has received validation...
► Artikel lesen
24.06.BRIEF-Capital Conquest Buys 2.6 Million Shares In Oasmia Pharmaceutical2
08.06.BRIEF-Oasmia Pharmaceutical Signs Phase 1B Trial Agreement With SAKK4
01.06.BRIEF-Oasmia Pharmaceutical Enters Into Settlement Agreement1
13.05.BRIEF-Oasmia Pharmaceutical: Outcome Of Strategic Review To Deliver Long-Term, Profitable Growth As A Specialty Pharma Company2
09.01.Oasmia Pharmaceutical AB: Oasmia to present at Biotech Showcase in San Francisco310Oasmia Pharmaceutical AB has been selected to present at the Biotech Showcase Conference and will be presenting its technology on Tuesday 14 January at 15:30 (3:30 pm), Track Yosemite C (Ballroom level). Biotech...
► Artikel lesen
30.12.19New number of shares and votes in Oasmia Pharmaceutical AB (publ)236The number of shares and votes in Oasmia Pharmaceutical AB (publ) has increased as a result of the preferential rights issue completed in December 2019. As a result of the preferential rights issue...
► Artikel lesen
30.12.19Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 - October 31, 2019262EVENTS IN SECOND QUARTER Oasmia ADSs were delisted from NASDAQ in the US to reduce complexity and costs.Oasmia recruited two General Managers to its management team.Oasmia published its annual report...
► Artikel lesen
09.12.19Oasmia Pharmaceutical AB: Final result of the rights issue in Oasmia277The final result of the rights issue in Oasmia Pharmaceutical AB (publ) ("Oasmia" or the "Company") amounts to 198,329,980 shares subscribed for with subscription rights, which corresponds to approximately...
► Artikel lesen
06.12.19Oasmia Pharmaceutical AB: Oasmia's rights issue has been oversubscribed295The preliminary result of the rights issue in Oasmia Pharmaceutical AB (publ) ("Oasmia" or the "Company"), in which the subscription period ended on 4 December 2019, amounts to 198,329,980 shares...
► Artikel lesen
27.11.19Oasmia Pharmaceutical AB: The CEO and Chairman of the Board of Oasmia buys subscription rights in the ongoing rights issue342Oasmia Pharmaceutical AB ("Oasmia" or "the Company") CEO Sven Rohmann and the Chairman of the Board Jörgen Olsson today announced that they have purchased 900,000 and 900,000 subscription rights respectively....
► Artikel lesen
19.11.19Oasmia Pharmaceutical AB: Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus295Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other...
► Artikel lesen
19.11.19Nasdaq Stockholm AB: Listing of subscription rights (TR) and paid subscription shares (BTA) in Oasmia Pharmaceutical AB288With effect from November 20, 2019, the subscription rights in Oasmia Pharmaceutical AB will be quoted on the list for Equity rights. Quotation will continue up until and including December 2, 2019....
► Artikel lesen
18.11.19Oasmia Pharmaceutical AB: Oasmia invites to investor meetings in connection to the rights issue310The Board of Directors of Oasmia Pharmaceutical AB (publ) ("Oasmia" or the "Company") invites to investor meetings in connection to the subscription period of the rights issue which runs from 20 November...
► Artikel lesen
14.11.19XFRA CAPITAL ADJUSTMENT INFORMATION - 15.11.2019 - 1230FOLGENDE WERTPAPIERE WERDEN AM 14.11.2019 CUM KAPITALMASSNAHME UND AM 15.11.2019 EX KAPITALMASSNAHME GEHANDELT. THE FOLLOWING SHARES ARE TRADED CUM CAPITAL ADJUSTMENT ON 14.11.2019 AND EX CAPITAL ADJUSTMENT...
► Artikel lesen
11.11.19Oasmia Pharmaceutical AB: Oasmia resolves on a rights issue of approximately SEK 399 million356Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other...
► Artikel lesen
06.11.19Extraordinary General Meeting in Oasmia Pharmaceutical AB on November 6, 2019272This is an unofficial in-house translation of the Swedish original. In case of differences theSwedish version shall prevail. Oasmia Pharmaceutical AB (publ) held an Extraordinary General Meeting...
► Artikel lesen
14.10.19Notice of extraordinary general meeting in Oasmia Pharmaceutical AB420The shareholders of Oasmia Pharmaceutical AB (the "Company") are hereby given notice of the extraordinary general meeting on Wednesday 6 November 2019, at 14:00 CET, at the offices of the Company, Vallongatan...
► Artikel lesen
14.10.19Oasmia Pharmaceutical AB: The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million520The Board of Directors in Oasmia Pharmaceutical AB ("Oasmia" or the "Company") today announces a notice to an extra general meeting on 6 November 2019. It is proposed that the extra general meeting...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1